March 28, 2025 07:00 AM EDTUpdated March 29, 12:45 AM
Peer Review

On the heels of staff cuts, CRISPR Ther­a­peu­tics COO de­parts; Changes ga­lore at Bi­cy­cle

Kathy Wong

Editor

→ Af­ter a 6-year run, CRISPR Ther­a­peu­tics COO Ju­lianne Bruno is step­ping out the door to pur­sue oth­er op­por­tu­ni­ties. Bruno’s de­par­ture …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

A service from the Financial Times